Hypoxia inducible factor-1 as a therapeutic target in cerebral ischemia

Current Signal Transduction Therapy

Volumn 4, Issue 3, 2009, Pages 162-173

  Aguilera, Penélope ^a   Vázquez Contreras, Edgar ^b   Gómez Martínez, Carlos Daniel ^c   Cárdenas, María Elena Chánez ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b DEPARTAMENTO DE PROCESOS Y TECNOLOGÍA   (Mexico)

^c UNIVERSIDAD AUTÓNOMA DE GUERRERO   (Mexico)

Author keywords

Cerebral ischemia; Hypoxia inducible factor; Ischemic preconditioning; Prolyl hydroxylase

Indexed keywords

ASPARAGINE; BAICALEIN; CATECHIN; CITRIC ACID; CLIOQUINOL; DEFEROXAMINE; ETHYL 3,4 DIHYDROXYBENZOATO; GALLIC ACID PROPYL ESTER; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METAL ION; NEUROPROTECTIVE AGENT; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; QUERCETIN; RECOMBINANT ERYTHROPOIETIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AMEBIASIS; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE EXPRESSION REGULATION; HUMAN; HYDROXYLATION; HYPERBARIC OXYGEN; ISCHEMIC PRECONDITIONING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 77951908242     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436209789057458     Document Type: Article

References (72)

1. Juttler E, Kohrmann M, Schellinger PD. Therapy for early reperfusion after stroke. Nat Clin Pract Cardiovasc Med 2006; 3: 656-63.
2. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-7.
3. Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007; 87: 179-97.
4. Chavez JC, LaManna JC. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: potential role of insulin-like growth factor-1. J Neurosci 2002; 22: 8922-31.
5. Prass K, Scharff A, Ruscher K, et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 2003; 34: 1981-6.
6. Baranova O, Miranda LF, Pichiule P, Dragatsis I, Johnson RS, Chavez JC. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J Neurosci 2007; 27: 6320-32.
7. Ginouvès A, Ilc K, Macías N, Pouysségur J, Berra E. PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci USA 2008; 105: 4745-50.
8. Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci 1999; 11: 4159-70.
9. Marti HJ, Bernaudin M, Bellail A, et al. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol 2000; 156: 965-76.
10. Rocha S. Gene regulation under low oxygen: holding your breath for transcription. Trends Biochem Sci 2007; 32: 389-97.
11. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001; 7: 345-50.
12. Ratan RR, Siddiq A, Aminova L, et al. Translation of ischemic preconditioning to the patient: prolyl hydroxylase inhibition and hypoxia inducible factor-1 as novel targets for stroke therapy. Stroke 2004; 35: 2687-9.
13. Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 2007; 80: 51-60.
14. Tang Y, Pacary E, Fréret T, et al. Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: identification of potential neuroprotective candidates for stroke. Neurobiol Dis 2006; 21: 18-28.
15. Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS, Eckardt KU. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 2007; 435: 221-45.
16. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007; 19: 223-9.
17. Pagé EL, Chan DA, Giaccia AJ, Levine M, Richard DE. Hypoxiainducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2008; 19: 86-94.
18. André H, Pereira TS. Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1alpha. J Biol Chem 2008; 283: 29375-84.
19. Minet E, Arnould T, Michel G, et al. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000; 468: 53-8.
20. Li L, Xiong Y, Qu Y, et al. The requirement of extracellular signalrelated protein kinase pathway in the activation of hypoxia inducible factor 1 alpha in the developing rat brain after hypoxiaischemia. Acta Neuropathol 2008; 115: 297-303.
21. Sperandio S, Fortin J, Sasik R, Robitaille L, Corbeil J, de Belle I. The transcription factor Egr1 regulates the HIF-1alpha gene during hypoxia. Mol Carcinog 2008; 48: 38-44.
22. Pagé EL, Robitaille GA, Pouysségur J, Richard DE. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 2002; 277: 48403-9.
23. Van Hoecke M, Prigent-Tessier AS, Garnier PE, et al. Evidence of HIF-1 functional binding activity to caspase-3 promoter after photothrombotic cerebral ischemia. Mol Cell Neurosci 2007; 34: 40-7.
24. Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene 2007; 26: 2027-38.
25. Schmid T, Zhou J, Brüne B. HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med 2004; 8: 423-31.
26. Chen C, Hu Q, Yan J, et al. Multiple effects of 2ME2 and D609 on the cortical expression of HIF-1alpha and apoptotic genes in a middle cerebral artery occlusion-induced focal ischemia rat model. J Neurochem 2007; 102: 1831-41.
27. Gidday JM. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 2006; 7: 437-48.
28. Kirino T. Ischemic tolerance. J Cereb Blood Flow Metab 2002; 22: 1283-96.
29. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 2007; 116: 173-91.
30. Bernaudin M, Nedelec AS, Divoux D, MacKenzie ET, Petit E, Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 2002; 22: 393-403.
31. Liu J, Narasimhan P, Yu F, Chan PH. Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin. Stroke 2005; 36: 1264-9.
32. Liu M, Alkayed NJ. Hypoxic preconditioning and tolerance via hypoxia inducible factor (HIF) 1alpha-linked induction of P450 2C11 epoxygenase in astrocytes. J Cereb Blood Flow Metab 2005; 25: 939-48.
33. Jones NM, Lee EM, Brown TG, Jarrott B, Beart PM. Hypoxic preconditioning produces differential expression of hypoxiainducible factor-1alpha (HIF-1alpha) and its regulatory enzyme HIF prolyl hydroxylase 2 in neonatal rat brain. Neurosci Lett 2006; 404: 72-7.
34. Li QF, Zhu YS, Jiang H. Isoflurane preconditioning activates HIF-1alpha, iNOS and Erk1/2 and protects against oxygen-glucose deprivation neuronal injury. Brain Res 2008; 1245: 26-35.
35. Li YX, Ding SJ, Xiao L, Guo W, Zhan Q. Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull 2008, 24: 89-95.
36. Gu GJ, Li YP, Peng ZY, et al. Mechanism of ischemic tolerance induced by hyperbaric oxygen preconditioning involves upregulation of hypoxia-inducible factor-1alpha and erythropoietin in rats. J Appl Physiol 2008; 104: 1185-91.
37. Peng Z, Ren P, Kang Z, et al. Up-regulated HIF-1alpha is involved in the hypoxic tolerance induced by hyperbaric oxygen preconditioning. Brain Res 2008; 1212: 71-8.
38. He W, Qian Zhong M, Zhu L, et al. Ginkgolides mimic the effects of hypoxic preconditioning to protect C6 cells against ischemic injury by up-regulation of hypoxia-inducible factor-1 alpha and erythropoietin. Int J Biochem Cell Biol 2008; 40: 651-62.
39. Jones NM, Bergeron M. Hypoxia-induced ischemic tolerance in neonatal rat brain involves enhanced ERK1/2 signaling. J Neurochem 2004; 89: 157-67.
40. Helton R, Cui J, Scheel JR, et al. Brain specific knock-out of hypoxia-inducible factor-1alpha reduces rather than increases hypoxic-ischemic damage. J Neurosci 2005; 25: 4099-4107. Erratum J Neurosci 2005; 25: 1 p following 4888.
41. Bernaudin M, Tang Y, Reilly M, Petit E, Sharp FR. Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J Biol Chem 2002; 277: 39728-38.
42. Chen H, Shi H. A reducing environment stabilizes HIF-2alpha in SH-SY5Y cells under hypoxic conditions. FEBS Lett 2008; 582: 3899-902.
43. Park SK, Dadak AM, Haase VH, Fontana L, Giaccia AJ, Johnson RS. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Mol Cell Biol 2003; 23: 4959-71.
44. Warnecke C, Weidemann A, Volke M, et al. The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res 2008; 314: 2016-27.
45. Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp 2006; 272: 15-25.
46. Cockman ME, Lancaster DE, Stolze IP, et al. Posttranslational hydroxylation of ankyrin repeats in IkappaB proteins by the hypoxia-inducible factor (HIF) asparaginyl hydroxylase, factor inhibiting HIF (FIH). Proc Natl Acad Sci USA 2006; 103: 14767-72.
47. Appelhoff RJ, Tian YM, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279: 38458-65.
48. Willam C, Maxwell PH, Nichols L, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol 2006; 41: 68-77.
49. Rantanen K, Pursiheimo J, Högel H, Himanen V, Metzen E, Jaa kkola PM. Prolyl hydroxylase PHD3 activates oxygen-dependent protein aggregation. Mol Biol Cell 2008; 19: 2231-40.
50. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci USA 2006; 103: 654-9.
51. Choi KO, Lee T, Lee N, et al. Inhibition of the catalytic activity of hypoxia-inducible factor-1alpha-prolyl-hydroxylase 2 by a MYNDtype zinc finger. Mol Pharmacol 2005; 68: 1803-9.
52. Choi SM, Choi KO, Lee N, Oh M, Park H. The zinc chelator, N, N, N', N'-tetrakis (2-pyridylmethyl) ethylenediamine, increases the level of nonfunctional HIF-1alpha protein in normoxic cells. Biochem Biophys Res Commun 2006; 343: 1002-8.
53. Li Q, Chen H, Huang X, Costa M. Effects of 12 metal ions on iron regulatory protein 1 (IRP-1) and hypoxia-inducible factor-1 alpha (HIF-1alpha) and HIF-regulated genes. Toxicol Appl Pharmacol 2006; 213: 245-55.
54. Davidson TL, Chen H, Di Toro DM, D'Angelo G, Costa M. Soluble nickel inhibits HIF-prolyl-hydroxylases creating persistent hypoxic signaling in A549 cells. Mol Carcinog 2006; 45: 479-89.
55. Zaman K, Ryu H, Hall D, et al. Protection from oxidative stressinduced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 1999; 19: 9821-30.
56. Mao X, Schimmer AD. The toxicology of Clioquinol. Toxicol Lett 2008; 182: 1-6.
57. Mao X, Li X, Sprangers R, et al. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia 2009; 23: 585-90.
58. Choi SM, Choi KO, Park YK, Cho H, Yang EG, Park H. Clioquinol, a Cu(II)/Zn(II) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells. J Biol Chem 2006; 281: 34056-63.
59. Siddiq A, Ayoub IA, Chavez JC, et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 2005; 280: 41732-43.
60. van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Combination of deferoxamine and erythropoietin: Therapy for hypoxia-ischemia induced brain injury in the neonatal rat? Neurosc Lett 2009; 451: 109-13.
61. Pan Y, Mansfield KD, Bertozzi CC, et al. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxiainducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 2007; 27: 912-25.
62. Koivunen P, Hirsilä M, Remes AM, Hassinen IE, Kivirikko KI, Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 2007; 282: 4524-32.
63. Hewitson KS, Liénard BM, McDonough MA, et al. Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 2007; 282: 3293-301.
64. Huang Y, Tsang SY, Yao X, Chen ZY. Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 177-84.
65. Liu C, Wu J, Gu J, et al. Baicalein improves cognitive deficits induced by chronic cerebral hypoperfusion in rats. Pharmacol Biochem Behav 2007; 86: 423-430.
66. van Leyen K, Kim HY, Lee SR, Jin G, Arai K, Lo EH. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke 2006; 37: 3014-3018.
67. Cho H, Lee HY, Ahn DR, et al. Baicalein induces functional hypoxia-inducible factor-1alpha and angiogenesis. Mol Pharmacol 2008; 74: 70-81.
68. Kasiganesan H, Sridharan V, Wright G. Prolyl hydroxylase inhibitor treatment confers whole-animal hypoxia tolerance. Acta Physiol (Oxf) 2007; 190: 163-9.
69. Aguilera P, Chánez-Cárdenas ME, Maldonado PD. In: Santamaría A, Jiménez ME, Pandalai SG, Eds. Recent advances in the use of antioxidant treatments in cerebral ischemia. Kerala India, Research Signpost 2007; 61-74.
70. Jeon H, Kim H, Choi D, et al. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol 2007; 71: 1676-84.
71. Tsukiyama F, Nakai Y, Yoshida M, et al. Gallate, the component of HIF-inducing catechins, inhibits HIF prolyl hydroxylase. Biochem Biophys Res Commun 2006; 351: 234-9.
72. McMahon S, Charbonneau M, Grandmont S, Richard DE, Dubois CM. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. J Biol Chem 2006; 281: 24171-81.